News
Displaying 141–150 of 508
-
Enhanced Implantable Miniature Telescope Moving into Clinical Trial for AMD Patients
Research NewsThe device is designed for people with late-stage AMD who have no treatment options
-
Opus Genetics Appoints Jennifer Hunt Chief Development Officer
In the PressBiopharma clinical development veteran to propel Opus’ AAV-based gene therapies for inherited retinal diseases toward patients.
-
Foundation Fighting Blindness to Host VISIONS 2022 Conference
Foundation NewsThe national conference will be held on June 17–18, featuring sessions with the latest research advancements, practical adapting and thriving, and an opportunity to connect with the blind and low vision community.
-
Foundation News
The Foundation Fighting Blindness, the world’s leading organization committed to finding treatments and cures for retinal degenerative diseases, will host an online continuing medical education (CME and COPE) course on inherited retinal disease gene therapies on Thursday, June 9, 2022, at 7:00 p.m. EDT.
-
Gene Knock-Out, Replacement Therapy for RP-RHO Performed Well in Lab Study
Research NewsEditas is planning IND-enabling studies of the two-part treatment in preparation for a clinical trial
-
Promising Results from Lab Study of Gene Therapy for Cone-Rod Dystrophy
Research NewsThe study is an important step toward a clinical trial of the approach
-
Encouraging Clinical Trial Results for Alkeus’ Stargardt Disease Treatment
Research NewsThe company is also conducting a Phase 3 clinical trial of the emerging therapy for geographic atrophy.
-
Webinar for the X-Linked Retinitis Pigmentosa (XLRP) Community
Research NewsThe Foundation Fighting Blindness recently held a webinar to provide details about an upcoming Externally-Led Patient Focused Drug Development (EL-PFDD) meeting for XLRP, and to provide background information about the Food and Drug Administration’s (FDA) drug review process.
-
Foundation Summit Highlights Robust Growth in Commercial Development for Retinal Disease Therapies
Foundation NewsThe Foundation’s Investing in Cures Summit (ICS), held on April 2, 2022, in Half Moon Bay, California, convened 175 researchers, industry executives, and constituents to present and discuss the expanding and accelerating commercial development of emerging therapies for retinal degenerative diseases.
-
Drug for Alcohol Abuse May Restore Vision for People with Retinal Diseases
Research NewsThe drug holds promise for enabling retinal-disease patients to get more vision from remaining photoreceptors
